NEW YORK – Tempus AI said Tuesday that it has acquired clinical trial patient matching company Deep 6 AI for an undisclosed amount.
Deep 6 AI uses artificial intelligence-based software to match patients with clinical trials by mining real-time structured and unstructured electronic medical record data from multiple sources, including academic medical centers, National Cancer Institute-designated cancer centers, and NCI community oncology research programs. The firm's research ecosystem includes more than 45 healthcare organizations and life sciences companies.
Structured data includes ICD-10 codes and demographic info like age and gender, while unstructured data includes physician notes, pathology reports, and laboratory results, according to Deep 6 AI's website. The company's software also returns partial results, showing which patients could qualify but are possibly missing a key lab result.
Deep 6 AI, founded in 2016 and based in Pasadena, California, previously partnered with Genomenon to gain insights about conditions like cancer, Parkinson's disease, and Wilson's disease.
"Deep 6's impressive integration infrastructure is well suited to complement our connectivity efforts, which are central to our ability to support physicians in delivering optimized care for their patients," Tempus CEO and Founder Eric Lefkofsky said in a statement. "This acquisition broadens our reach, adding even more providers to our platform, and enhances our ability to deploy critical applications like Next, which helps physicians close care gaps, and Time, which helps patients find potentially life-saving clinical trials."
Tempus' Next is an AI-based application that provides insights from multimodal, longitudinal patient data including medical imaging data, EMR data, laboratory results, pathology reports, and clinician notes. The Next application is available for oncology and cardiology and is intended to identify and minimize care gaps.
The firm's Time Trial Program is a network that supports rapid patient identification, site activation, and enrollment for certain precision medicine clinical trials. The company uses proprietary trial matching software and methods to identify relevant clinical trials personalized to each patient's molecular and clinical data, according to Tempus' website.